» Articles » PMID: 39651971

3. Prevention or Delay of Diabetes and Associated Comorbidities: Standards of Care in Diabetes-2025

Overview
Journal Diabetes Care
Specialty Endocrinology
Date 2024 Dec 9
PMID 39651971
Affiliations
Soon will be listed here.
Abstract

The American Diabetes Association (ADA) "Standards of Care in Diabetes" includes the ADA's current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, an interprofessional expert committee, are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA's clinical practice recommendations and a full list of Professional Practice Committee members, please refer to Introduction and Methodology. Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.

Citing Articles

Incremental Cost-Effectiveness Ratios (ICERs) and Revised Metformin Cost-Effectiveness Conclusions in the Diabetes Prevention Program/ Diabetes Prevention Program Outcomes Study.

Alolayan S, Eguale T, Segal A, Doucette J, Rittenhouse B Am J Lifestyle Med. 2025; 15598276251315415.

PMID: 39850322 PMC: 11752154. DOI: 10.1177/15598276251315415.


Diabetes in Korean Adults: Prevalence, Management, and Comorbidities.

Yu S Diabetes Metab J. 2025; 49(1):22-23.

PMID: 39828975 PMC: 11788548. DOI: 10.4093/dmj.2024.0844.

References
1.
Spence J, Viscoli C, Inzucchi S, Dearborn-Tomazos J, Ford G, Gorman M . Pioglitazone Therapy in Patients With Stroke and Prediabetes: A Post Hoc Analysis of the IRIS Randomized Clinical Trial. JAMA Neurol. 2019; 76(5):526-535. PMC: 6515584. DOI: 10.1001/jamaneurol.2019.0079. View

2.
Hudspeth B . Power of Prevention: The Pharmacist's Role in Prediabetes Management. Diabetes Spectr. 2018; 31(4):320-323. PMC: 6243216. DOI: 10.2337/ds18-0021. View

3.
Herold K, Bundy B, Long S, Bluestone J, DiMeglio L, Dufort M . An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes. N Engl J Med. 2019; 381(7):603-613. PMC: 6776880. DOI: 10.1056/NEJMoa1902226. View

4.
Kim J, Ahn C, Fang S, Lee H, Park J . Association between metformin dose and vitamin B12 deficiency in patients with type 2 diabetes. Medicine (Baltimore). 2019; 98(46):e17918. PMC: 6867725. DOI: 10.1097/MD.0000000000017918. View

5.
de Jager J, Kooy A, Lehert P, Wulffele M, van der Kolk J, Bets D . Long term treatment with metformin in patients with type 2 diabetes and risk of vitamin B-12 deficiency: randomised placebo controlled trial. BMJ. 2010; 340:c2181. PMC: 2874129. DOI: 10.1136/bmj.c2181. View